Trial Profile
Phase IV, Multicenter, Single-blind, Positive-controlled, Parallel Group Study of Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Adm.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 16 Jan 2010 New trial record